AGC Biologics partners I-MAB Biopharma supporting late-stage clinical trials

KUALA LUMPUR, Dec 14 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new partnership with I-MAB Biopharma.

The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.

AGC Biologics operates multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle cell culture facility.

The site is designed for capacity and technological flexibility, and has an extensive variety of single-use and stainless steel systems that meet the latest guidelines required for cGMP compliance, with the Seattle site having a long history of successful inspections by the FDA and approved for commercial production.

Based on a statement, these features and capabilities combined make the AGC Biologics Seattle facility an ideal location to support I-MAB’s goals and bring this treatment through its next clinical phase.

“We look forward to partnering with a true pioneer in innovative clinical research and development, and working together to help bring I-MAB's product through the final clinical stages and to commercialisation,” said Jean-Baptiste Agnus, Chief Business Officer of AGC Biologics.

“Our team in Seattle is an ideal customer-focused group of scientists to help I-MAB in its promising journey for this treatment.”

AGC Biologics’ Seattle facility has capabilities for developing a wide range of mammalian and microbial programs, and has delivered several approved commercial products. Its global network spans the US, Europe, and Asia.

To learn more, visit www.agcbio.com.

-- BERNAMA